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Background: Adults being investigated for TB in South Africa experience high mortality, yet causes of death
(CoD) are not well deﬁned. We determined CoD in this population using verbal autopsy (VA), and compared
HIV- and TB-associated CoD using physician-certiﬁed verbal autopsy (PCVA) and InterVA-4 software.
Methods: All contactable consenting caregivers of participants who died during a trial comparing Xpert MTB/
RIF to smear microscopy were interviewed using the WHO VA tool. CoD were assigned using PCVA and
InterVA-4. Kappa statistic (K) and concordance correlation coefﬁcient (CCC) were calculated for comparison.
Results: Among 231 deaths, relatives of 137 deceased were interviewed. Of the 137 deceased 76 (55.4%)
were males, median age 41 years (IQR 33–50). PCVA assigned 70 (51.1%) TB immediate CoD (44 [62.8%] pul-
monary TB; 26 [37.1%] extra-pulmonary TB); 21 (15.3%) HIV/AIDS-related; and 46 (33.5%) other CoD.
InterVA-4 assigned 48 (35.0%) TB deaths; 49 (35.7%) HIV/AIDS-related deaths; and 40 (29.1%) other CoD.
Agreement between PCVA and InterVA-4 CoD was slight at individual level (K=0.20; 95% CI 0.10–0.30) and
poor at population level (CCC 0.67; 95% CI 0.38–0.99).
Conclusions: TB and HIV are leading CoD among adults being investigated for TB. PCVA and InterVA agree-
ment at individual level was slight and poor at population level. VA methodology needs further development
where TB and HIV are common.
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Introduction
TB is a leading cause of death in South Africa1 and is a public
health priority, with an estimated 380 0002 cases in 2013, among
whom 62% were also living with HIV.3 WHO has set global tar-
gets to reduce TB mortality by 75% in 2025 compared to 2015
ﬁgures as a baseline.2 To track the reduction in TB mortality,
accurate data on numbers of TB deaths are needed. Cause of
death is most accurately assigned using pathological autopsy.4
However, pathological autopsies are logistically difﬁcult and rarely
performed. In areas where not all deaths occur in health facilities
and causes of death are not determined, poor vital statistics, as
well as the need to better understand the distribution of cause of
death at population level, have led to verbal autopsy (VA) being
used to estimate cause of death. This involves interviewing care-
givers about the signs, symptoms, medical history and circum-
stances surrounding an individual’s death.5 VA interview data can
be interpreted to estimate cause of death using methods such as
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physician-certiﬁed verbal autopsy (PCVA) and computer-coded
verbal autopsy (CCVA), with PCVA being the most widely used
method. CCVA uses software that employs algorithms and prob-
abilistic methods (including InterVA-4 [http://www.interva.net/]),
while the PCVA method involves at least two physicians examin-
ing each record and attempting to reach a consensus on cause
of death using codes from the 10th version of the International
Classiﬁcation of Diseases (ICD-10).6,7
The XTEND trial, a pragmatic cluster-randomised trial embed-
ded in the South African national roll-out of Xpert MTB/RIF, com-
pared mortality over six months among adults investigated for TB
using Xpert MTB/RIF vs smear microscopy as the initial diagnostic
test.8 XTEND found high mortality in adults being investigated for
TB, with no difference in mortality at 6 months between the study
arms.8 The cohort of XTEND participants who died, presented a
unique opportunity to evaluate VA methodologies in a cohort with
high TB/HIV prevalence. The aim of this paper was to use VA to
assign cause of death, among adults being investigated for TB
with a particular interest in TB, and to compare cause of death
assigned by PCVA to that assigned by a CCVA method (InterVA-4).
Methods
XTEND study
The parent XTEND trial is described in detail elsewhere.8 Between
June and November 2012, a representative sample of 4656 con-
senting participants who were ≥18 years, planning to live in the
study catchment area for more than 8 months, identiﬁed by clinic
staff as needing investigation for TB and providing sputum for TB
testing were enrolled into the study. At enrolment, participants
provided contact details and those of close relatives or friends.
Vital status was ascertained by contacting participants, their next
of kin or friends by telephone and, if necessary, conducting home
visits. Vital status of participants was further ascertained by
reviewing the Department of Home Affairs vital statistics register.
Verbal autopsy
All XTEND participants who died during the study were eligible for
the VA sub-study, including some who died more than 6 months
post-enrolment and hence did not contribute to the XTEND primary
outcome. Demographic details and past medical history of
deceased participants were extracted from the XTEND database,
but were not available to staff doing VA interviews nor to physicians
assigning cause of death. The XTEND database also included case
note reviews where TB treatment start dates and antiretroviral
treatment (ART) start dates were obtained. Caregivers, deﬁned as a
relative or friend closely associated with the participant at time of
death, were invited to participate by telephonic contact, or if unsuc-
cessful, home visit. Lay counsellors, trained in administering the
standardized 2012 WHO VA tool and in grief counselling, adminis-
tered the questionnaire. The tool comprised of closed questions
with ‘yes’, ‘no’, or ‘don’t know’ responses and a narrative section.
The caregiver recounted the events leading up to the participant’s
death, detailing information about the deceased’s signs, symp-
toms, medical history, and circumstances preceding death in the
narrative section.5 Time from enrolment to death was deﬁned as
period from enrolment to date of death. Time from enrolment to
TB treatment initiation was the period from enrolment to date of
TB treatment initiation and time from enrolment to ART initiation
was the period from enrolment to date of ART initiation.
Interpretation of verbal autopsies using PCVA
PCVA involved two physicians independently assigning immediate
and underlying cause of death using ICD-10 guidelines, based on
VA data, including the caregiver’s narrative for each decedent.
Where different immediate or underlying causes of death were
assigned by the physicians, a consensus meeting was held; if no
consensus was reached, the case was referred to a third independ-
ent physician. If still no consensus was reached, the case was clas-
siﬁed ‘indeterminate’. Physicians were aware that all decedents
were participants in the XTEND trial and had been investigated for
TB. For individual cause of death analysis, the following ICD-10
codes were considered to be HIV-related deaths: B20 (HIV result-
ing in infectious and parasitic diseases), B21 (HIV disease resulting
in malignant neoplasms), B22 (HIV disease resulting in other speci-
ﬁed diseases), B23 (other conditions associated with HIV) and B24
(unspeciﬁed HIV disease). ICD-10 codes A15 (respiratory TB, bac-
teriologically and histologically conﬁrmed) and A16 (respiratory TB,
not conﬁrmed bacteriologically or histologically) were categorised
as pulmonary TB (PTB) while A17 (TB of nervous system), A18 (TB
of other organs) and A19 (miliary TB) as extra-pulmonary TB
(EPTB).9 Individual cause of death assigned by PCVA were pro-
cessed further using mortality medical data system (MMDS) soft-
ware, which generates underlying cause of death from multiple
causes of death.10 The output generated by MMDS was cate-
gorised into WHO 2012 VA causes of death groups; cause speciﬁc
mortality fractions were calculated by dividing the number of
deaths assigned to a group by the total number of deaths.5,10
Interpretation of verbal autopsies using InterVA-4
InterVA version 4.03 RC1 is software that uses Bayesian probabil-
istic theory to assign cause of death. The software generates up
to three probable causes of death for each case based on a pre-
determined algorithm with the cause of death assigned the high-
est likelihood being referred to as the most probable cause of
death.11–13 VA data were imported into InterVA-4, set at high HIV
and low malaria prevalence for our study setting. InterVA-4
assigns only PTB as a TB-related cause of death, classifying all
EPTB as ‘other unspeciﬁed infectious diseases’. Speciﬁcity of
InterVA-4 in assigning HIV-related cause of death has previously
been reported to be 90.1% (95% CI 88.7–91.4%).14 The probable
cause of death generated for each individual were further pro-
cessed to generate population cause speciﬁc mortality fractions.
All respondents gave written informed consent, or witnessed
verbal consent if unable to read and write.
Comparing InterVA-4 and PCVA
The two methods assign a wide range of cause of death but for
this study we concentrated on HIV/AIDS- and TB-related deaths.
At individual level, we focused on the most probable cause of
death assigned by InterVA-4, compared with underlying cause
of death generated by MMDS for PCVA. For TB deaths, we com-
pared PTB deaths assigned by PCVA and by InterVA-4. For HIV
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deaths, ICD-10 codes (B20–24) assigned by physicians were
grouped together and compared with HIV/AIDS-related deaths
assigned by InterVA-4. For individual causes of death assigned,
the level of agreement between the two methods was esti-
mated using Cohen’s kappa (Κ) statistic with a 95% CI. Κ=1
would indicate perfect agreement, and Κ=0 would indicate
agreement no better than chance.15 Cause speciﬁc mortality
fractions generated by the two methods were compared using
Lin’s concordance correlation coefﬁcient (CCC) which ranges
from −1 to +1 with +1 being perfect agreement and 0 showing
no agreement.16 All analyses were done using Stata (version 13,
Stata Corp LP, College Station, TX, USA).
Results
A total of 231 XTEND participants died between 8 June 2012
and 31 June 2013. From 1 August to 29 November 2013, 231
interviews were attempted with caregivers. Of these 138
(59.8%) were completed; 68 (29.4%) caregivers could not be
traced and 25 (10.8%) refused to be interviewed. Interviews
were conducted within a median time of 11 months (IQR 8–12
months) after deaths had occurred. One interview was excluded
due to a missing narrative section leaving 137 for analysis.
Among the 137 decedents, 76 (55.4%) were male and the
median age was 41 years (IQR 33–50). Ninety-seven (70.8%)
had self-reported being HIV-positive with median self-reported
CD4 count 118 (IQR 52–290) cells/μL. Baseline characteristics of
those who were included were similar to those who were not
included except for number of TB symptoms reported at enrol-
ment (Table 1). Furthermore there was no difference in time
from enrolment to death between the two groups. A total of 41
participants were started on TB treatment and 28 (20.4%) had
a VA done. Median time from enrolment to TB treatment was
11 days (IQR 7–33) in those with a VA vs 15 days (IQR 5–30) in
those without a VA; this did not differ between the two groups.
A total of 162 participants self-reported being HIV-positive in
Table 1. Characteristics of deceased participants who had verbal autopsy vs those who did not
Variables Verbal autopsy done Verbal autopsy not done p-value
Characteristics at baseline n=137 n=94
Male gender, n (%) 76 (55.4) 57 (60.6) NS
Age, years (median, IQR) 41 (33–50) 37 (31–48) NS
Country of origin, n (%)a
South Africa 128 (93.4) 84 (89.4)
Non-South African 9 (6.5) 9 (9.6) NS
Self-reported HIV status at enrolment, n (%)a
Positive 97 (70.8) 65 (69.1)
Negative 15 (10.9) 11 (11.7)
Unknown 25 (18.2) 17 (18.1) NS
Self-reported CD4 count (median, IQR)a 118 (52–290) 199 (103–253) NS
No. of TB symptoms reported at enrolment, n (%)a
0 0 (0) 2 (2.1)
1 15 (10.9) 4 (4.3)
2 34 (24.8) 16 (17.0)
3 38 (27.7) 36 (38.3)
4 50 (36.5) 35 (37.2) 0.05
Body mass index (kg/m2)a
<18.5 26 (18.9) 22 (23.4)
18.5–24.9 74 (54.0) 56 (59.5)
25–29.9 20 (14.6) 8 (8.5)
30+ 17 (12.4) 7 (7.4) NS
HIV and TB treatment initiation, death
Time from enrolment to death, days (median, IQR)b 64 (31–115) 57 (28–113) NS
No. started on TB treatment, n (%)
Overall n=41 (17.7%) 28 (20.4) 13 (13.8) NS
Time from enrolment to TB treatment initiation, days (median, IQR) 11 (7–33) 15 (5–30) NS
No. started on ART after enrolment, n=35 (%) 23 (65.7) 12 (34.2) NS
Time from enrolment to ART initiation, days (median, IQR) 25 (9–48) 15 (8–40) NS
ART: antiretroviral therapy; NS: not signiﬁcant.
a Data missing for one participant in the group without a verbal autopsy.
b Data missing for 12 participants.
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the study and 61 (37.6%) had evidence of being initiated on
ART. Of the 61, 35 (57%) started ART after enrolment into
XTEND. Median time from enrolment to ART initiation was not
different between the groups (Table 1).
PCVA assigned cause of death
PCVA assigned immediate and underlying cause of death for
134 (98.0%) VAs; three (2.2%) VAs were indeterminate
(Table 2). Of the 134 with a cause of death, 95 (70.9%) were
assigned without requiring a consensus meeting and 39
(28.5%) after a consensus meeting. Among the 137 decedents,
the most common immediate cause of death assigned was TB
(70 decedents, 51.1%). Of these 70 TB deaths, 44 (63%) were
attributed to PTB, of which eight (18%) were classiﬁed as bac-
teriologically conﬁrmed as reported on VA. EPTB was assigned
as cause of death in 26/70 (37%) TB deaths. Of these, 11 (42%)
were TB of the nervous system, 10 (38%) miliary TB and 5
(19%) TB of other organs; 57/70 (81%) of those assigned an
immediate TB cause of death were assigned an underlying HIV
cause of death by the physicians. HIV/AIDS-related immediate
cause of death were assigned in 21/137 (15.3%) decedents;
gastrointestinal diseases in seven (5.1%) decedents; pneumonia
in ﬁve (3.6%); cardiac disease and respiratory ailments in four
(3.0%) each; renal failure and malignant neoplasm in three
(2.0%) each; while liver disease and intentional self-harm were
in two (1.5%) each (Table 2). Cause speciﬁc mortality fractions
were calculated after PCVA causes of death were processed by
MMDS software: HIV/AIDS-related deaths accounted for 66.4%
of PCVA deaths; PTB for 9.5%; cardiac disease for 2.9%; and
malignant neoplasms, gastrointestinal diseases and accident/
self harm for 2.2% each (Table 3).
InterVA-4 assigned cause of death
InterVA-4 assigned cause of death to 136 (99.2%) decedents;
one (0.7%) was classiﬁed as indeterminate. Of the 137 dece-
dents, 48 (35.0%) were assigned a most probable cause of
death of PTB, 49 (35.7%) an HIV/AIDS-related cause, and 14
(10.2.%) a malignancy-related cause of death. Only one dece-
dent was assigned an ‘other unspeciﬁed infectious diseases’
cause of death by InterVA-4 (Table 2). InterVA-4 assigned 16
decedents with more than one cause of death, 13 were
assigned two, and three were assigned three causes of death.
Of the 16 with more than one cause of death, three (18.7%)
had HIV as a less probable cause and four (25.0%) had TB as
less probable cause of death. Only one decedent with a most
probable cause of death of PTB had HIV assigned as a less prob-
able cause and also one with HIV as a most probable cause of
death had PTB assigned as a less probable cause. InterVA-4
cause speciﬁc mortality fractions were calculated using all
assigned causes of death: PTB accounted for 33.2% of deaths;
HIV/AIDS for 32.8%; malignant neoplasms for 9.6%; and
respiratory ailments for 4.9% (Table 3).
Table 2. Immediate cause of death assigned by physician-certiﬁed verbal autopsy compared with ‘most probable’ cause of death assigned by
InterVA-4 (n=137)
Physician-certiﬁed verbal autopsy InterVA-4
Cause of death n (%) n (%)
Pulmonary TB 44 (32.1) 48 (35.0)
Not bacteriologically-conﬁrmed 36 (26.0) NA
Bacteriologically-conﬁrmed 8 (6.0) NA
Extrapulmonary TB 26 (19.0) NA
TB of nervous system 11 (8.0) NA
Miliary TB 10 (7.0) NA
TB of other organs 5 (4.0) NA
HIV/AIDS-related deaths 21 (15.3) 49 (35.7)
Gastrointestinal diseases 7 (5.1) 4 (3.0)
Pneumonia 5 (3.6) 4 (3.0)
Cardiac disease/failure 4 (3.0) 5 (3.6)
Respiratory ailments 4 (3.0) 2 (1.5)
Renal failure 3 (2.0) 1 (0.7)
Malignant neoplasm 3 (2.0) 14 (10.2)
Liver diseases 2 (1.5) 1 (0.7)
Intentional self-harm/poisoning 2 (1.5) 1 (0.7)
Meningitis 1 (0.7 ) 0 (0.0)
Indeterminate/unspeciﬁed 4 (3.0) 1 (0.7)
Other 11 (8.0) 7 (5.1)
Total 137 137
NA: not applicable.
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Comparing InterVA-4 and PCVA cause of death
A direct comparison of the single underlying cause of death
assigned by MMDS for PCVA and the most probable cause of
death assigned by InterVA-4 showed agreement in 65/137
(47.4%) decedents with kappa statistic 0.20 (95% CI 0.10–0.30);
representing slight agreement (Table 4). Comparison of cause
speciﬁc mortality fractions assigned by PCVA and InterVA
showed a CCC of 0.67 (95% CI 0.38–0.97), which was poor
(Table 3).
Discussion
The XTEND study is the largest cohort to date of adults being
investigated for TB. In this sub-study, we used VA to investigate
cause of death, which showed that about half (51% based on
PCVA and 35% based on InterVA-4) the deaths were attributed
to TB. These ﬁndings might be surprising as these were people
accessing health care who had investigation for TB initiated and
who had submitted at least one sputum specimen for smear
microscopy or Xpert MTB/RIF. Though one might hope that peo-
ple who had TB investigations initiated should not die of TB,
some patients may have already been very sick at the time TB
investigation was initiated, as illustrated by the 18.9% with BMI
<18.5 and the 64.2% reporting three or four TB symptoms. If
these cause of death data are correct, it suggests that persons
are presenting for care too late, or that the current health sys-
tem is failing to identify and treat persons who have TB, or both.
It could also be that the health system is too slow to diagnose
TB, resulting in delays in TB treatment initiation. This latter pos-
sibility was suggested by data from the XTEND trial which
showed median time to starting TB treatment of 7 days8 which
is a little longer than the Department of Health recommended
2–5 days.17 HIV-related disease was the second most common
cause of death, consistent with absence of ART at enrolment
being a risk factor for death among XTEND participants.8
Adults being investigated for TB have been studied far less
often than those starting TB treatment, and where cause of
death data exist, they are generally from hospitals rather than
primary health care clinics. The high proportion of deaths attrib-
utable to TB was similar to studies using pathological autopsy
to assign cause of death. An autopsy study in South Africa
among hospitalised HIV-positive adults either on, or eligible for,
ART showed that 66% died of TB, while only 27% were on TB
treatment at time of death and 33% had never been treated for
TB prior to death.18 In Zambia, a study amongst hospitalised
adults, mostly HIV-positive (81%), reported that 62% of deaths
were attributed to TB and 26% were never treated for TB prior
to death.19 A recent systematic review among HIV-positive
adults and children reported that TB was a primary cause of
death in 91.4% (95% CI 85.5–97) of those diagnosed at aut-
opsy.20 Another study in South Africa seeking to understand
cause of death among ART initiators dying in hospital using VA
and hospital case reviews also reported similar ﬁndings where
mortality attributable to TB was 44.3%.21
Our study compared PCVA and InterVA-4 methods of assign-
ing cause of death at individual and population level. The major-
ity of studies comparing these methodologies have been done
in community settings in health and demographic surveillance
system sites where VAs are done for all persons who die. In our
study, when comparing immediate and most probable cause of
death, PCVA assigned more deaths to TB than InterVA-4. This
could be because InterVA-4 can only assign PTB as a TB-related
death and assigns EPTB to other infectious diseases, while PCVA
allows deaths to be assigned as either PTB or EPTB, so EPTB
deaths are not misclassiﬁed. PCVA and InterVA-4 models have
been compared in other populations and have shown fair to
moderate agreement.22–24 A study conducted in a health and
demographic surveillance system in Kenya, collecting data on
cause of death over a 6 year period amongst children <5 years
and adults aged ≥18 years, showed that PCVA assigned 9.9% of
deaths to PTB and 34% to HIV/AIDS while InterVA assigned 31%
to PTB and 16% to HIV/AIDS (Κ=0.27, 95% CI 0.25–0.30).22 In
Ethiopia, data on cause of death collected over a 2 year period
from adults aged ≥14 years in a health and demographic
Table 3. Comparison of cause speciﬁc mortality fractions as
assigned by physician certiﬁed verbal autopsy and mortality
medical data system and InterVA-4
Cause of death PCVA CSMF (%) InterVA-4 CSMF (%)
HIV/AIDS related 66.4 32.8
Pulmonary TB 9.5 33.2
Cardiac diseases 2.9 2.9
Malignant neoplasm 2.2 9.6
Gastrointestinal diseases 2.2 0.5
Accident/self-harm 2.2 0.7
Diabetes mellitus 1.5 1.0
Respiratory ailments 1.5 4.9
Liver diseases 1.5 1.0
Other diseases 8.0 6.2
Unknown 2.2 7.4
Total 100 100
CSMF: cause speciﬁc mortality fractions; PCVA: physician-certiﬁed
verbal autopsy.
Concordance correlation coefﬁcient: 0.67 (95% CI 0.38–0.97).
Table 4. Agreement between ’most probable’ cause of death
assigned by InterVA-4 and single underlying cause of death
assigned by physician-certiﬁed verbal autopsy and mortality
medical data system for 137 deceased XTEND participants
Physician-certiﬁed verbal autopsy
InterVA-4 TB HIV Other Total
TB 10 32 6 48
HIV 1 38 10 49
Other 2 21 17 40
Total 13 91 33 137
Cohen’s kappa: 0.20; 95% CI 0.10–0.30.
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surveillance system showed that PCVA assigned 23% to PTB
and InterVA-3 assigned 36% deaths to PTB (Κ=0.5, 95% CI
0.4–0.6).23 When comparing cause speciﬁc mortality fractions
assigned by PCVA and InterVA, InterVA assigned more TB than
PCVA. This is largely because ICD-10 coding rules require that
assignment of a single cause of death in individuals with
immediate cause of death of TB and underlying cause of death
of HIV be classiﬁed as an HIV/AIDS-related death.9 This
resulted in 57 (81%) of immediate TB deaths assigned at indi-
vidual level being classiﬁed as HIV/AIDS-related deaths after
processing by the MMDS software. A recent study done in Asia
and Africa comparing VA cause of death as assigned by PCVA
and InterVA-4 also reported a CCC of 0.83 (95% CI 0.75–0.91)
between the methods which was higher than the 0.67 found in
our study.25
PCVA assigned more immediate PTB cause of death in our
study compared to health and demographic surveillance system
studies, most likely because our study included people with
symptoms suggestive of TB who were identiﬁed by clinic staff as
needing TB investigation. It is also possible that, because the
physicians who interpreted the VAs knew that all study partici-
pants were being investigated for TB, this could have biased
them to choose TB as a cause of death.
A major strength of our study is that our study population
was a large systematic sample of adults being investigated for
TB in a real-world setting. Our results can be generalised to
adults being investigated for TB in similar settings and also to
people with TB symptoms severe enough to need investigation.
We also managed to perform the majority of VA interviews
within one year of death which made it easier for respondents
to recall exact events leading to a participant’s death.
A study limitation is that we could not conduct a VA for
everyone who died, and could thus have missed other causes of
death which has implications on the proﬁle of causes reported
in this population. A higher proportion of decedents who had VA
done had started TB treatment compared to those who died
but did not have a VA done. Those who were on TB treatment
would have been easier to contact because they were already
in care, therefore overestimating TB as a cause of death in the
study.
Our ﬁndings show that when interpreting VA data using
either PCVA or InterVA-4 for adults being investigated for TB, TB
is a leading cause of death. These results also suggest that the
current TB diagnostic pathway is inadequate as people with TB
disease may still be missed or commenced on treatment too
late. The fact that HIV was identiﬁed as the second most com-
mon cause of death points to the importance of integrated TB
and HIV care and linkage into care for both diseases. The health
service through implementation science research needs to ﬁnd
ways to facilitate access to TB and HIV care for persons who
need to navigate both services. We recommend that adults
being investigated for TB need to be aware of their HIV status,
as data from XTEND also showed that people were more likely
to die if they were HIV-positive and not on ART or if their HIV
status was unknown.8 Intensiﬁed TB screening also needs to be
improved as the sensitivity of the current screening tool is sub-
optimal and a diagnostic test for TB with high sensitivity and
speciﬁcity that could be used in primary health care settings is a
priority. We also recommend that current CCVA methods should
be improved to include EPTB. Research has shown that 88% of
HIV-positive individuals with autopsy evidence of TB have disse-
minated disease20; if VA methods do not classify EPTB as TB, a
large number of TB deaths will be missed.
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